Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Difelikefalin - Cara Therapeutics

Drug Profile

Difelikefalin - Cara Therapeutics

Alternative Names: CKD-943; CR 845; FE 202845; KORSUVA; MR13A9

Latest Information Update: 08 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Cara Therapeutics; Chong Kun Dang; Kissei Pharmaceutical; Maruishi Pharmaceutical
  • Class Antipruritics; Opioid analgesics; Peptides
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Postoperative pain

Highest Development Phases

  • Phase III Postoperative pain; Pruritus
  • Phase II Pain
  • Phase I Renal failure

Most Recent Events

  • 06 Dec 2019 Cara Therapeutics plans a phase III trial for Pruritus in 2020
  • 06 Dec 2019 Cara Therapeutics completes a phase II trial for Pruritus (associated with stage III-V chronic kidney disease)in USA (PO, Tablet)
  • 03 Dec 2019 Efficacy and adverse event data from phase II trial for Pruritus (associated with stage III-V chronic kidney disease) released by Cara Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top